Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy
- PMID: 40565464
- PMCID: PMC12193533
- DOI: 10.3390/healthcare13121437
Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy
Abstract
Obesity and Type 2 Diabetes Mellitus (T2DM) are interrelated chronic conditions whose global prevalence continues to rise, posing significant clinical and socioeconomic challenges. Their pathophysiological intersection-commonly referred to as "diabesity"-is sustained by a complex interplay of mechanisms, including visceral adipose tissue inflammation, macrophage polarization, disrupted insulin signaling, and adipokine imbalance. These processes contribute to chronic low-grade systemic inflammation, impair pancreatic β-cell function, and exacerbate glucose intolerance. This review critically explores the mechanistic connections between obesity and T2DM, with a focus on recent advances in pharmacological therapies-such as GLP-1 receptor agonists, SGLT2 inhibitors, and dual GIP/GLP-1 receptor agonists-alongside evidence-based lifestyle modifications and bariatric procedures. By integrating current translational and clinical findings, we aim to provide a comprehensive perspective to support the development of more effective and individualized treatment strategies for diabesity.
Keywords: Type 2 Diabetes Mellitus; lifestyle intervention; obesity; physical activity; visceral adiposity.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2. Cochrane Database Syst Rev. 2017. PMID: 28489279 Free PMC article.
-
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.Cochrane Database Syst Rev. 2018 Sep 24;9(9):CD011798. doi: 10.1002/14651858.CD011798.pub2. Cochrane Database Syst Rev. 2018. PMID: 30246878 Free PMC article.
-
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091. BMJ. 2021. PMID: 33975892
-
Lifestyle interventions for the treatment of women with gestational diabetes.Cochrane Database Syst Rev. 2017 May 4;5(5):CD011970. doi: 10.1002/14651858.CD011970.pub2. Cochrane Database Syst Rev. 2017. PMID: 28472859 Free PMC article.
-
Oral anti-diabetic agents for women with established diabetes/impaired glucose tolerance or previous gestational diabetes planning pregnancy, or pregnant women with pre-existing diabetes.Cochrane Database Syst Rev. 2017 Oct 18;10(10):CD007724. doi: 10.1002/14651858.CD007724.pub3. Cochrane Database Syst Rev. 2017. PMID: 29045765 Free PMC article.
References
-
- Lamberto M., Mantovan M., Novi R.F. Essential Obesity: An Unresolved Clinical Problem. Considerations on Central Appetite Stimulants and Inhibitors. Minerva Endocrinol. 1993;18:27–35. - PubMed
Publication types
LinkOut - more resources
Full Text Sources